Could an arthritis drug help treat schizophrenia?

NCT ID NCT05622201

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether rituximab, an anti-inflammatory drug used for conditions like multiple sclerosis, can improve symptoms in adults with schizophrenia spectrum disorders. About 123 participants aged 18-55 will receive rituximab or a placebo added to their usual treatment. The study also looks at blood markers and brain scans to understand who might benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rituximab
What this could lead to
If it works, this could point toward a new treatment option for some people with schizophrenia by targeting inflammation.
What could go wrong
This is a small, early-phase trial. Rituximab is not proven for psychosis, and results may not apply to everyone. Side effects from immune suppression are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Örebro university hospital

    Örebro, Örebro County, 701 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.